Aurobindo Pharma Ltd

NSE: AUROPHARMA · BSE: 524804 · Pharmaceuticals & Biotechnology · 63 announcements

Aurobindo Pharma Ltd news stories on ALFA NewsRead the news →

Share price: ₹1,682.00
Market cap: ₹97,691 Cr
Revenue (annual): ₹33,653 Cr
Net profit (annual): ₹3,505 Cr
P/E (TTM): 24.8×Sector 47.3×
Promoter holding: 51.88%+0.06% QoQ
FII holding: 16.38%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Merger & Restructuring 3 Business Update 3 Regulatory Approval 1 Product Launch 1 Earnings Call 1 Annual General Meeting 1 Acquisition 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

3 announcements with these filters

12 Sep 2026 12:41 IST NSE

Merger & Restructuring

Aurobindo Pharma Merger & Restructuring Worth ₹9.5 Cr

Aurobindo Pharma's subsidiary, A1 Biochem Labs (India), invested USD 1,000,000 (approx. ₹9.5 Crore) to incorporate and capitalize a new US subsidiary, A1 Biochem USA Inc.

Value: ₹9.50 Cr

Read the filing ↗

1 Sep 2026 10:10 IST NSE

Merger & Restructuring

Aurobindo Pharma Merger & Restructuring Worth ₹5 Cr

Aurobindo Pharma's subsidiary, Apitoria Pharma, incorporated a new wholly owned subsidiary named Avogent Lifesciences. The initial capital subscription for this pharmaceutical entity is Rs. 5 Crore.

Value: ₹5.00 Cr

Read the filing ↗

13 Aug 2026 16:22 IST BSE

Merger & Restructuring

Aurobindo Pharma Merger & Restructuring Worth ₹0.1 Cr

Aurobindo Pharma incorporated a new wholly owned subsidiary, 'Auropharm Overseas Limited'. The company subscribed to the subsidiary's share capital of Rs. 0.1 Crore.

Value: ₹0.10 Cr

Read the filing ↗